COMMUNIQUÉS West-GlobeNewswire

Sarms Vs Steroids – The Best Sarms And Legal Steroids For Cutting, Bulking And Bodybuilding In 2025 Tested And Rated – By Crazy Bulk.

23/04/2025 - 21:34

New York City, April 23, 2025 (GLOBE NEWSWIRE) -- SARMs are a rather new proposition on the market compared to steroids. An enthusiast of the fitness culture would admit to having heard about SARMs or steroids at some [...]

Best SARMS for Cutting and Bulking to Buy 2025 - Best SARMS for Sale for Muscle Growth, Fat Loss and Bodybuilding- By CrazyBulk

23/04/2025 - 21:45

Albany, New York, April 23, 2025 (GLOBE NEWSWIRE) -- If you’re looking to transform your physique with lean muscle growth, SARMs (Selective Androgen Receptor Modulators) are incredibly popular. Bodybuilders are buying [...]

Mounfit Under Review: Natural Mounjaro Ingredients Recipe to Lose Weight Safely

23/04/2025 - 21:49

Mounfit Offers a Plant-Based, GLP-1 Inspired Weight Loss Supplement as a Natural Alternative to Mounjaro in 2025 Aurora, Colorado, April 23, 2025 (GLOBE NEWSWIRE) -- Introduction Understanding the Modern Weight Loss [...]

Galapagos Reports First Quarter 2025 Financial Results, Recent Business Highlights and Near-Term Catalysts

23/04/2025 - 22:01

First U.S. patient dosed in ATALANTA-1 study of GLPG5101 Mantle cell lymphoma (MCL), a high-unmet-need hematological malignancy, selected as lead indication for the GLPG5101 program; Pivotal development planned to start [...]

OrthoPediatrics Corp. to Report First Quarter Financial Results on May 7, 2025

23/04/2025 - 22:05

WARSAW, Ind., April 23, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS a company focused exclusively on advancing the field of pediatric orthopedics, today announced [...]

RxSight, Inc. to Report First Quarter 2025 Financial Results on May 7, 2025

23/04/2025 - 22:05

ALISO VIEJO, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, [...]

Sight Sciences Announces the Release of its Sustainability Report

23/04/2025 - 22:05

The Sustainability Report provides data for 2022 through 2024 on the Company’s environmental, social, and governance initiatives MENLO PARK, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT [...]

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

23/04/2025 - 22:05

BOSTON, April 23, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective on January 31, 2025 [...]

Cardiff Oncology Announces a Second Patent for the Treatment of mCRC for Bev-Naïve Patients

23/04/2025 - 22:05

The claims cover combination treatment of onvansertib + bev for all bev-naïve patients including RAS-mutated and RAS wild type mCRC across all lines of therapy through 2043 SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- [...]

Aligos Therapeutics Announces Eight Abstracts Accepted for Presentation at the EASL Congress 2025

23/04/2025 - 22:05

SOUTH SAN FRANCISCO, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies [...]

Inotiv, Inc. to Report Fiscal 2025 Second Quarter Financial Results and Host Conference Call on Wednesday, May 7, 2025

23/04/2025 - 22:05

WEST LAFAYETTE, Ind., April 23, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and [...]

Candel Therapeutics Announces Oral Presentation of Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025

23/04/2025 - 22:05

NEEDHAM, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies [...]

Resmed Inc. Announces Results for the Third Quarter of Fiscal Year 2025

23/04/2025 - 22:05

Year-over-year revenue grows 8% , operating profit up 14% , non-GAAP operating profit up 13% Operating cash flow of $579 million Note: A webcast of Resmed’s conference call will be available at 4:30 p.m. ET today at [...]

OraSure to Announce First Quarter 2025 Financial Results and Host Earnings Call on May 7th

23/04/2025 - 22:05

BETHLEHEM, Pa., April 23, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering first quarter 2025 financial results and certain business [...]

Zentalis Pharmaceuticals Announces Poster Presentation at 2025 ASCO Annual Meeting

23/04/2025 - 22:05

SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for [...]

Corvus Pharmaceuticals to Present New Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on May 8, 2025

23/04/2025 - 22:08

Data from Cohorts 1-3 of trial to be presented in an oral session and poster at the Society for Investigative Dermatology (SID) 2025 Annual Meeting Company to discuss data on its first quarter 2025 business update [...]

Iovance Biotherapeutics Announces Participation in Upcoming Scientific Congresses

23/04/2025 - 22:15

SAN CARLOS, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating [...]

Palvella Therapeutics Announces Abstract Highlighting the Estimated Diagnosed Prevalence and Annual Incidence of Lymphatic Malformations in the U.S. Accepted for Poster Presentation at the 82nd Annual Meeting of the Society for Investigative Dermatology

23/04/2025 - 22:15

Quantitative analysis of medical claims indicates an estimated 44,553 to 92,967 diagnosed U.S. patients with lymphatic malformations (LMs) with cutaneous involvement Estimates of annual incidence of LMs with cutaneous [...]

Xilio Therapeutics to Present Updated Phase 2 Data for Vilastobart, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Combination with Atezolizumab in Patients with Microsatellite Stable Colorectal Cancer at the 2025 ASCO Annual Meeting

23/04/2025 - 22:30

WALTHAM, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living [...]